Market Movers: Nordstrom Privatization, Novo Nordisk Rebound, and Tech MA
In midday trading, Nordstrom shares fell over 1% following its \$6.25 billion buyout, while Novo Nordisk shares rebounded after a previous drop; Honda surged over 11% on merger talks with Nissan; Xerox rose 7% on its Lexmark acquisition; Despegar.com soared 32% on Prosus's buyout; and Traws Pharma j...
Market Movers: Nordstrom Privatization, Novo Nordisk Rebound, and Tech MA
In midday trading, Nordstrom shares fell over 1% following its \$6.25 billion buyout, while Novo Nordisk shares rebounded after a previous drop; Honda surged over 11% on merger talks with Nissan; Xerox rose 7% on its Lexmark acquisition; Despegar.com soared 32% on Prosus's buyout; and Traws Pharma j...
Progress
16% Bias Score
DOJ Sues CVS for Alleged Role in Opioid Crisis
The US Justice Department sued CVS, alleging the pharmacy chain unlawfully dispensed massive quantities of opioids and other controlled substances for over a decade, ignoring red flags and prioritizing speed over safety, contributing to the opioid crisis.
DOJ Sues CVS for Alleged Role in Opioid Crisis
The US Justice Department sued CVS, alleging the pharmacy chain unlawfully dispensed massive quantities of opioids and other controlled substances for over a decade, ignoring red flags and prioritizing speed over safety, contributing to the opioid crisis.
Progress
56% Bias Score
Africa's Pharmaceutical Dependence Hinders Health Emergency Response
Michel Sidibé, former UNAIDS executive director, decried Africa's vulnerability due to its dependence on external pharmaceutical production, impacting its ability to manage health emergencies; a strategic plan targets 24 essential medicines to address this, emphasizing the need for local production ...
Africa's Pharmaceutical Dependence Hinders Health Emergency Response
Michel Sidibé, former UNAIDS executive director, decried Africa's vulnerability due to its dependence on external pharmaceutical production, impacting its ability to manage health emergencies; a strategic plan targets 24 essential medicines to address this, emphasizing the need for local production ...
Progress
44% Bias Score
Greece Launches New Obesity Drug Amidst Booming Market
Greece launched tirzepatide, a weekly injectable obesity drug costing \"253.05 EUR\", promising \"20%\" weight loss; high demand is expected, reflecting a \"200 billion USD\" market projection by 2030 and innovation in transdermal delivery systems.
Greece Launches New Obesity Drug Amidst Booming Market
Greece launched tirzepatide, a weekly injectable obesity drug costing \"253.05 EUR\", promising \"20%\" weight loss; high demand is expected, reflecting a \"200 billion USD\" market projection by 2030 and innovation in transdermal delivery systems.
Progress
44% Bias Score
Morgan Stanley's 2025 Market Outlook: Opportunities and Risks
Morgan Stanley's 2025 market outlook highlights "diabesity" treatments, Edge AI, and Canadian rail stocks as investment opportunities, while Wells Fargo identifies inflation, high valuations, and geopolitical risks as potential downsides for the S&P 500, which it forecasts to reach 7007.
Morgan Stanley's 2025 Market Outlook: Opportunities and Risks
Morgan Stanley's 2025 market outlook highlights "diabesity" treatments, Edge AI, and Canadian rail stocks as investment opportunities, while Wells Fargo identifies inflation, high valuations, and geopolitical risks as potential downsides for the S&P 500, which it forecasts to reach 7007.
Progress
40% Bias Score
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Despite Reduced COVID-19 Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the year ending November 2023, down from previous years due to decreased COVID-19 vaccine and treatment sales, but still comparable to pre-pandemic levels; the subsidiary manages operations for most Pfizer entities outside the U.S.
Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Despite Reduced COVID-19 Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the year ending November 2023, down from previous years due to decreased COVID-19 vaccine and treatment sales, but still comparable to pre-pandemic levels; the subsidiary manages operations for most Pfizer entities outside the U.S.
Progress
40% Bias Score
Spain's Methylphenidate Shortage to End in Early 2025
The Spanish Agency of Medicines and Medical Products (Aemps) reports that methylphenidate shortages for ADHD treatment, affecting patients since April 2024 due to increased global demand and production issues at Janssen-Cilag, will be resolved by early 2025 thanks to increased production from variou...
Spain's Methylphenidate Shortage to End in Early 2025
The Spanish Agency of Medicines and Medical Products (Aemps) reports that methylphenidate shortages for ADHD treatment, affecting patients since April 2024 due to increased global demand and production issues at Janssen-Cilag, will be resolved by early 2025 thanks to increased production from variou...
Progress
24% Bias Score
dm's Online Pharmacy Entry Shakes Up German Pharmaceutical Market
dm, a German drugstore chain, plans to launch an online pharmacy for non-prescription drugs, creating competition for existing pharmacies and causing share prices of competitors to fall; the company may also expand into telemedicine and in-store vaccinations.
dm's Online Pharmacy Entry Shakes Up German Pharmaceutical Market
dm, a German drugstore chain, plans to launch an online pharmacy for non-prescription drugs, creating competition for existing pharmacies and causing share prices of competitors to fall; the company may also expand into telemedicine and in-store vaccinations.
Progress
44% Bias Score
Pfizer Stock Up 5% on Positive 2025 Outlook
Pfizer's stock rose 5% on December 17, 2024, after projecting $61-$64 billion in 2025 revenue and $2.80-$3.00 adjusted earnings per share, driven by acquisitions and cost-cutting to offset declining Covid-19 vaccine sales.
Pfizer Stock Up 5% on Positive 2025 Outlook
Pfizer's stock rose 5% on December 17, 2024, after projecting $61-$64 billion in 2025 revenue and $2.80-$3.00 adjusted earnings per share, driven by acquisitions and cost-cutting to offset declining Covid-19 vaccine sales.
Progress
36% Bias Score
Trump's Post-Election Press Conference: Healthcare, Tech, and Foreign Policy in Focus
President-elect Trump, in his first post-election press conference, addressed vaccine policy, pharmaceutical costs, potential appointments, and foreign policy, revealing potential shifts in healthcare, technology, and international relations.
Trump's Post-Election Press Conference: Healthcare, Tech, and Foreign Policy in Focus
President-elect Trump, in his first post-election press conference, addressed vaccine policy, pharmaceutical costs, potential appointments, and foreign policy, revealing potential shifts in healthcare, technology, and international relations.
Progress
48% Bias Score
Mexico Launches Large-Scale Medicine Purchase to Combat Shortages
The Mexican government announced a two-year, 135 billion-peso bulk purchase of medicines to address chronic shortages, involving direct negotiations with pharmaceutical companies, digital inventory management, and adjustments to distribution.
Mexico Launches Large-Scale Medicine Purchase to Combat Shortages
The Mexican government announced a two-year, 135 billion-peso bulk purchase of medicines to address chronic shortages, involving direct negotiations with pharmaceutical companies, digital inventory management, and adjustments to distribution.
Progress
40% Bias Score
Moderna Stock Plunges Amidst Financial Uncertainty and Anti-Vaccine Concerns
Moderna's stock, once a pandemic star, has plummeted 90% from its peak, fueled by concerns over its reliance on the Covid-19 vaccine, an underwhelming RSV vaccine, and the potential impact of anti-vaccine sentiment within the incoming Trump administration.
Moderna Stock Plunges Amidst Financial Uncertainty and Anti-Vaccine Concerns
Moderna's stock, once a pandemic star, has plummeted 90% from its peak, fueled by concerns over its reliance on the Covid-19 vaccine, an underwhelming RSV vaccine, and the potential impact of anti-vaccine sentiment within the incoming Trump administration.
Progress
52% Bias Score